Personalis, Inc. to Present at the American Association for Cancer Research (AACR) Annual Meeting 2019

Menlo Park, CA – March 31, 2019 – Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present one oral presentation and five posters at the American Association for Cancer Research (AACR) Annual Meeting being held this year in Atlanta, GA from March 31 – April 3, 2019.

Personalis presentations will highlight how fundamental oncology research informs the ongoing evolution of our leading immunogenomics analysis platform. The presentations will also detail the alignment between our genomics solutions and AACR’s 2019 theme: Integrative Cancer Science • Global Impact • Individualized Patient Care. 

Following is a list of abstracts that will be presented at the meeting.

Session ID / Poster Number Title & Presenter Day & Time Location
MS.BSB01.01 (oral presentation)
Comprehensive immunogenomic profiling of anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms
March 31
3:05 pm – 3:20 pm
Room B206
2512 / 8
A comprehensive genomics platform for precision immunotherapy: Simultaneously characterizing the tumor and tumor microenvironment from a single FFPE sample
April 1
1 pm – 5 pm
Poster section
T-cell receptor repertoire profiling using an augmented transcriptome
April 2
8 am – 12 pm
Poster section
3788 / 5
Sensitive detection of oncoviruses integrated into a comprehensive tumor immuno-genomics platform
April 2
1 pm – 5 pm
Poster section
4536 / 9
Applying Immuno-Peptidomics and Machine Learning to Improve Neoantigen Prediction for Therapeutic and Diagnostic Use
April 3
8 am – 12 pm
Poster section
4695 / 8
Development and Validation of an Accurate Exome-Scale cfDNA Detection Platform
April 3
8 am – 12 pm
Poster section

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit and follow Personalis on Twitter (@PersonalisInc).

Media Contact for Personalis:
Jennifer Havlek